Neomed Labs Pacific Biomarkers PAIRimmune are now Nexelis

Our Team – Board of Directors

Our strategic orientations are guided and supported by our Board of Directors composed of experienced partners from Ampersand Capitals, a Boston-based growth equity healthcare middle market investor founded in the late 80s.

Eric B. Lev

Partner, Ampersand Capital

Eric, who joined Ampersand in 2013, has 15 years of middle market healthcare investment experience. His board seats have included CutisPharma, Genoptix, LakePharma and Nexcelom. Most recently, he spent seven years as a member of the investment team at Water Street Healthcare Partners. Prior to Water Street, Eric worked at Beckman Coulter and One Equity Partners. Eric holds a BA in Economics from Northwestern University and a MBA from the University of Chicago.

Herbert H. Hooper

Managing Partner, Ampersand Capital

Herb is a managing partner at Ampersand Capitalsince 2002. Prior to Ampersand, Herb was a co-founder and chief scientific officer of Aclara Biosciences, a pioneering lab-on-a chip company that completed an IPO in 2000. Herb holds a PhD in Chemical Engineering from the University of California, Berkeley, and a BS in Chemical Engineering from NC State University. He has served as a board member for over a dozen public and private life sciences companies. Herb also serves on the Advisory Board for UC Berkeley’s College of Chemistry.

Laurence R. McCarthy

Operating Partner, Ampersand Capital

Larry, who joined as an Operating Partner in 2007, serves as a Board member of Bako and Genoptix. Previously, Larry was the Chairman and Chief Technology Officer of Focus Diagnostics, where he built Focus from a $2 million business to a leading esoteric lab with over $80 million in revenues before its acquisition by Quest Diagnostics in 2006. Prior to Focus, Larry held senior positions at Boehringer Mannheim and Becton Dickinson. He holds a PhD in Microbiology from the University of New Hampshire and served on the faculty of Johns Hopkins and at the University of North Carolina.

Benoit Bouche

President and Chief Executive Officer (CEO)

Benoit spent over 30 years growing healthcare businesses and solving fast growth-related issues as an entrepreneur, investor, advisor, or board member.

He created and led the leading continental European clinical stage CRO in the 90s and has been instrumental in the development of Mapi from 2001, then a few dozen employees’ company, until its sale to Icon with 800 people and revenues north of €100m in 2017.

Benoit has a dual scientific (PharmD Pharmacy 1984; PhD Pharmaceutical Sciences/Biotechnology 1986) and business (Advanced Management Program Harvard Business School 2002) education. His professional background enabled him to gain an in-depth knowledge of all aspects of a healthcare venture stage company and to favor understanding and collaboration between scientists and business persons.

In the investment banking field, he was at Puilaetco (a Belgian brokerage firm since acquired by KBC) head of equity research team between 1998 and 2002, joined Bryan Garnier (a leading M&A boutique and brokerage firm) to create the healthcare practice and then became a senior advisor, healthcare to IMAP, a 400 M&A professionals network until 2017.

He has been instrumental in the emergence of several funds investing in private and public innovative healthcare companies. Several times ranked by Thomson Reuters as a top five healthcare analyst, he also sourced and led the execution of over 40 M&A transactions and financing rounds for biotechnology and medical device, and outsourcing companies.

He joined NEOMED-LABS in 2017 with the assignment to transform a vaccine R&D unit that had been spun-off from GSK in 2015 with 55 people into a global immunology laboratory services player. He led a MBO backed by Ampersand Capital in July 2018, acquired Pacific Biomarkers and PAIRimmune since that date and the company now rebranded as Nexelis has more than tripled its size in 2 years.

back to top
contact us now

contact us

  • This field is for validation purposes and should be left unchanged.